Congress nixes expanding FTC powers
This article was originally published in The Tan Sheet
Executive Summary
Congress drops a proposal to dramatically expand the Federal Trade Commission's authorities, much to the relief of the dietary supplement and other industries. Conference committee members agreed June 25 to a version of the Restoring American Financial Stability Act, H.R. 4173, without a provision to allow FTC to adopt regulations via Administrative Procedure Act rulemaking procedures. The Natural Products Association and the Council for Responsible Nutrition lobbied against the provision (1"The Tan Sheet" April 26, 2010). NPA and CRN support enhancing FTC's enforcement capabilities, but say the changes the House proposed were unfair and should not be part of legislation about unrelated issues. "There's nothing about giving FTC any additional powers that had anything to do with Wall Street," said NPA Executive Director and CEO John Gay. "We believe that there needs to be more activity by FTC going after some of the bad actors in the supplement industry," said Mike Greene, CRN's VP of governmental relations
You may also be interested in...
FTC Provision In Finance Reform Bill Could Bite Supplement Firms
Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker